Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist

Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2010, Pages 27-35

  Akers, Wendell S ^a   Oh, Jennifer J ^b   Oestreich, Julie H ^b   Ferraris, Suellen ^b   Wethington, Mary ^c   Steinhubl, Steven R ^d  

^a Department of Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Clinical Research Organization   (United States)

^d Medicines Company Zurich   (Switzerland)

Author keywords

Cangrelor; Clopidogrel; P2Y12; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ADENOSINE DIPHOSPHATE; CANGRELOR; PADGEM PROTEIN; PURINERGIC P2Y12 RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BLURRED VISION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; HYPERHIDROSIS; HYPOTENSION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; MALE; OLFACTORY NERVE DISEASE; PARESTHESIA; PAROSMIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VOLUNTEER;

ADENOSINE MONOPHOSPHATE; ADULT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2;

EID: 72749128296     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344986     Document Type: Article

References (11)

1. Mehta S., Yusuf S., Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358: 527-533.
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 ; 352: 1179-1189.
3. Steinhubl SR, Berger, PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288: 2411-2420.
4. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 ; 366: 1607-1621.
5. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist?s panacea or the surgeon?s headache ? Eur Heart J. 2005 ; 26: 576-583.
6. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 ; 111: 2560-2564.
7. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006 ; 151: 689.e1-689.e10.
8. Storey RF, Oldroyd KG, Wilcox RG Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001 ; 85: 401-407.
9. Jacobsson F., Swahn E., Wallentin L., Dellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther. 2002 ; 24: 752-765.
10. van Giezen JJ, Humphries RG Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005 ; 31: 195-204.
11. Heptinstall S., Johnson A., Glenn JR, White AE Adenine nucleotide metabolism in human blood-important roles for leukocytes and erythrocytes. J Thromb Haemost. 2005 ; 3: 2331-2339.